Cargando…
OpenSAFELY: impact of national guidance on switching anticoagulant therapy during COVID-19 pandemic
BACKGROUND: Early in the COVID-19 pandemic, the National Health Service (NHS) recommended that appropriate patients anticoagulated with warfarin should be switched to direct-acting oral anticoagulants (DOACs), requiring less frequent blood testing. Subsequently, a national safety alert was issued re...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595296/ https://www.ncbi.nlm.nih.gov/pubmed/34785588 http://dx.doi.org/10.1136/openhrt-2021-001784 |
_version_ | 1784600170386685952 |
---|---|
author | Curtis, Helen J MacKenna, Brian Walker, Alex J Croker, Richard Mehrkar, Amir Morton, Caroline Bacon, Seb Hickman, George Inglesby, Peter Bates, Chris Evans, David Ward, Tom Cockburn, Jonathan Davy, Simon Bhaskaran, Krishnan Schultze, Anna Rentsch, Christopher T Williamson, Elizabeth Hulme, William Tomlinson, Laurie Mathur, Rohini Drysdale, Henry Eggo, Rosalind M Wong, Angel Yun Forbes, Harriet Parry, John Hester, Frank Harper, Sam Douglas, Ian Smeeth, Liam Goldacre, Ben |
author_facet | Curtis, Helen J MacKenna, Brian Walker, Alex J Croker, Richard Mehrkar, Amir Morton, Caroline Bacon, Seb Hickman, George Inglesby, Peter Bates, Chris Evans, David Ward, Tom Cockburn, Jonathan Davy, Simon Bhaskaran, Krishnan Schultze, Anna Rentsch, Christopher T Williamson, Elizabeth Hulme, William Tomlinson, Laurie Mathur, Rohini Drysdale, Henry Eggo, Rosalind M Wong, Angel Yun Forbes, Harriet Parry, John Hester, Frank Harper, Sam Douglas, Ian Smeeth, Liam Goldacre, Ben |
collection | PubMed |
description | BACKGROUND: Early in the COVID-19 pandemic, the National Health Service (NHS) recommended that appropriate patients anticoagulated with warfarin should be switched to direct-acting oral anticoagulants (DOACs), requiring less frequent blood testing. Subsequently, a national safety alert was issued regarding patients being inappropriately coprescribed two anticoagulants following a medication change and associated monitoring. OBJECTIVE: To describe which people were switched from warfarin to DOACs; identify potentially unsafe coprescribing of anticoagulants; and assess whether abnormal clotting results have become more frequent during the pandemic. METHODS: With the approval of NHS England, we conducted a cohort study using routine clinical data from 24 million NHS patients in England. RESULTS: 20 000 of 164 000 warfarin patients (12.2%) switched to DOACs between March and May 2020, most commonly to edoxaban and apixaban. Factors associated with switching included: older age, recent renal function test, higher number of recent INR tests recorded, atrial fibrillation diagnosis and care home residency. There was a sharp rise in coprescribing of warfarin and DOACs from typically 50–100 per month to 246 in April 2020, 0.06% of all people receiving a DOAC or warfarin. International normalised ratio (INR) testing fell by 14% to 506.8 patients tested per 1000 warfarin patients each month. We observed a very small increase in elevated INRs (n=470) during April compared with January (n=420). CONCLUSIONS: Increased switching of anticoagulants from warfarin to DOACs was observed at the outset of the COVID-19 pandemic in England following national guidance. There was a small but substantial number of people coprescribed warfarin and DOACs during this period. Despite a national safety alert on the issue, a widespread rise in elevated INR test results was not found. Primary care has responded rapidly to changes in patient care during the COVID-19 pandemic. |
format | Online Article Text |
id | pubmed-8595296 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-85952962021-11-17 OpenSAFELY: impact of national guidance on switching anticoagulant therapy during COVID-19 pandemic Curtis, Helen J MacKenna, Brian Walker, Alex J Croker, Richard Mehrkar, Amir Morton, Caroline Bacon, Seb Hickman, George Inglesby, Peter Bates, Chris Evans, David Ward, Tom Cockburn, Jonathan Davy, Simon Bhaskaran, Krishnan Schultze, Anna Rentsch, Christopher T Williamson, Elizabeth Hulme, William Tomlinson, Laurie Mathur, Rohini Drysdale, Henry Eggo, Rosalind M Wong, Angel Yun Forbes, Harriet Parry, John Hester, Frank Harper, Sam Douglas, Ian Smeeth, Liam Goldacre, Ben Open Heart Health Care Delivery, Economics and Global Health Care BACKGROUND: Early in the COVID-19 pandemic, the National Health Service (NHS) recommended that appropriate patients anticoagulated with warfarin should be switched to direct-acting oral anticoagulants (DOACs), requiring less frequent blood testing. Subsequently, a national safety alert was issued regarding patients being inappropriately coprescribed two anticoagulants following a medication change and associated monitoring. OBJECTIVE: To describe which people were switched from warfarin to DOACs; identify potentially unsafe coprescribing of anticoagulants; and assess whether abnormal clotting results have become more frequent during the pandemic. METHODS: With the approval of NHS England, we conducted a cohort study using routine clinical data from 24 million NHS patients in England. RESULTS: 20 000 of 164 000 warfarin patients (12.2%) switched to DOACs between March and May 2020, most commonly to edoxaban and apixaban. Factors associated with switching included: older age, recent renal function test, higher number of recent INR tests recorded, atrial fibrillation diagnosis and care home residency. There was a sharp rise in coprescribing of warfarin and DOACs from typically 50–100 per month to 246 in April 2020, 0.06% of all people receiving a DOAC or warfarin. International normalised ratio (INR) testing fell by 14% to 506.8 patients tested per 1000 warfarin patients each month. We observed a very small increase in elevated INRs (n=470) during April compared with January (n=420). CONCLUSIONS: Increased switching of anticoagulants from warfarin to DOACs was observed at the outset of the COVID-19 pandemic in England following national guidance. There was a small but substantial number of people coprescribed warfarin and DOACs during this period. Despite a national safety alert on the issue, a widespread rise in elevated INR test results was not found. Primary care has responded rapidly to changes in patient care during the COVID-19 pandemic. BMJ Publishing Group 2021-11-16 /pmc/articles/PMC8595296/ /pubmed/34785588 http://dx.doi.org/10.1136/openhrt-2021-001784 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Health Care Delivery, Economics and Global Health Care Curtis, Helen J MacKenna, Brian Walker, Alex J Croker, Richard Mehrkar, Amir Morton, Caroline Bacon, Seb Hickman, George Inglesby, Peter Bates, Chris Evans, David Ward, Tom Cockburn, Jonathan Davy, Simon Bhaskaran, Krishnan Schultze, Anna Rentsch, Christopher T Williamson, Elizabeth Hulme, William Tomlinson, Laurie Mathur, Rohini Drysdale, Henry Eggo, Rosalind M Wong, Angel Yun Forbes, Harriet Parry, John Hester, Frank Harper, Sam Douglas, Ian Smeeth, Liam Goldacre, Ben OpenSAFELY: impact of national guidance on switching anticoagulant therapy during COVID-19 pandemic |
title | OpenSAFELY: impact of national guidance on switching anticoagulant therapy during COVID-19 pandemic |
title_full | OpenSAFELY: impact of national guidance on switching anticoagulant therapy during COVID-19 pandemic |
title_fullStr | OpenSAFELY: impact of national guidance on switching anticoagulant therapy during COVID-19 pandemic |
title_full_unstemmed | OpenSAFELY: impact of national guidance on switching anticoagulant therapy during COVID-19 pandemic |
title_short | OpenSAFELY: impact of national guidance on switching anticoagulant therapy during COVID-19 pandemic |
title_sort | opensafely: impact of national guidance on switching anticoagulant therapy during covid-19 pandemic |
topic | Health Care Delivery, Economics and Global Health Care |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595296/ https://www.ncbi.nlm.nih.gov/pubmed/34785588 http://dx.doi.org/10.1136/openhrt-2021-001784 |
work_keys_str_mv | AT opensafelyimpactofnationalguidanceonswitchinganticoagulanttherapyduringcovid19pandemic AT curtishelenj opensafelyimpactofnationalguidanceonswitchinganticoagulanttherapyduringcovid19pandemic AT mackennabrian opensafelyimpactofnationalguidanceonswitchinganticoagulanttherapyduringcovid19pandemic AT walkeralexj opensafelyimpactofnationalguidanceonswitchinganticoagulanttherapyduringcovid19pandemic AT crokerrichard opensafelyimpactofnationalguidanceonswitchinganticoagulanttherapyduringcovid19pandemic AT mehrkaramir opensafelyimpactofnationalguidanceonswitchinganticoagulanttherapyduringcovid19pandemic AT mortoncaroline opensafelyimpactofnationalguidanceonswitchinganticoagulanttherapyduringcovid19pandemic AT baconseb opensafelyimpactofnationalguidanceonswitchinganticoagulanttherapyduringcovid19pandemic AT hickmangeorge opensafelyimpactofnationalguidanceonswitchinganticoagulanttherapyduringcovid19pandemic AT inglesbypeter opensafelyimpactofnationalguidanceonswitchinganticoagulanttherapyduringcovid19pandemic AT bateschris opensafelyimpactofnationalguidanceonswitchinganticoagulanttherapyduringcovid19pandemic AT evansdavid opensafelyimpactofnationalguidanceonswitchinganticoagulanttherapyduringcovid19pandemic AT wardtom opensafelyimpactofnationalguidanceonswitchinganticoagulanttherapyduringcovid19pandemic AT cockburnjonathan opensafelyimpactofnationalguidanceonswitchinganticoagulanttherapyduringcovid19pandemic AT davysimon opensafelyimpactofnationalguidanceonswitchinganticoagulanttherapyduringcovid19pandemic AT bhaskarankrishnan opensafelyimpactofnationalguidanceonswitchinganticoagulanttherapyduringcovid19pandemic AT schultzeanna opensafelyimpactofnationalguidanceonswitchinganticoagulanttherapyduringcovid19pandemic AT rentschchristophert opensafelyimpactofnationalguidanceonswitchinganticoagulanttherapyduringcovid19pandemic AT williamsonelizabeth opensafelyimpactofnationalguidanceonswitchinganticoagulanttherapyduringcovid19pandemic AT hulmewilliam opensafelyimpactofnationalguidanceonswitchinganticoagulanttherapyduringcovid19pandemic AT tomlinsonlaurie opensafelyimpactofnationalguidanceonswitchinganticoagulanttherapyduringcovid19pandemic AT mathurrohini opensafelyimpactofnationalguidanceonswitchinganticoagulanttherapyduringcovid19pandemic AT drysdalehenry opensafelyimpactofnationalguidanceonswitchinganticoagulanttherapyduringcovid19pandemic AT eggorosalindm opensafelyimpactofnationalguidanceonswitchinganticoagulanttherapyduringcovid19pandemic AT wongangelyun opensafelyimpactofnationalguidanceonswitchinganticoagulanttherapyduringcovid19pandemic AT forbesharriet opensafelyimpactofnationalguidanceonswitchinganticoagulanttherapyduringcovid19pandemic AT parryjohn opensafelyimpactofnationalguidanceonswitchinganticoagulanttherapyduringcovid19pandemic AT hesterfrank opensafelyimpactofnationalguidanceonswitchinganticoagulanttherapyduringcovid19pandemic AT harpersam opensafelyimpactofnationalguidanceonswitchinganticoagulanttherapyduringcovid19pandemic AT douglasian opensafelyimpactofnationalguidanceonswitchinganticoagulanttherapyduringcovid19pandemic AT smeethliam opensafelyimpactofnationalguidanceonswitchinganticoagulanttherapyduringcovid19pandemic AT goldacreben opensafelyimpactofnationalguidanceonswitchinganticoagulanttherapyduringcovid19pandemic |